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Background: Peritoneal carcinomatosis is a common metastatic pattern in ovarian, gastric, 
colorectal, and appendiceal cancer; systemic chemotherapy is the current standard of 
care for peritoneal metastatic disease; however, in a subset of patients its beneficial effect 
remains questionable. More effective perioperative chemotherapy is needed.
Materials and methods: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is 
a new treatment that applies chemotherapeutic drugs into the peritoneal cavity as an 
aerosol under pressure. It’s a safe and feasible approach that improves local bioavailability 
of chemotherapeutic drugs as compared with conventional intraperitoneal chemotherapy. 
Till now the drugs used in PIPAC for the treatment of the peritoneal carcinomatosis (PC) 
are cisplatin, doxorubicin, and oxaliplatin; as of yet, there are no in vivo data comparing 
different drug formulations and dosage schedules of PIPAC. Pegylated liposomal 
doxorubicin 1.5 mg/sm was aerosolized in PIPAC procedures.
Results: Pharmacokinetics analysis of 10 procedures performed with conventional 
doxorubicin solution at the dose of 1.5 mg/m2 were compared to 15 procedures with the 
same dose of pegylated liposomal doxorubicin (PLD). 
Significant differences between experimental groups were detected by one-way ANOVA 
followed by Bonferroni correction; a p value < 0.05 was considered statistically significant. 
A statistically different doxorubicin tissue concentration was observed for the doxorubicin 
solution compared to pegylated liposomal doxorubicin in the right parietal peritoneum and 
right diaphragm. In the Caelyx® series a mean tissue concentration of 1.27 ± 1.33 mg/g was 
reported, while in the second one we registered a mean concentration of 3.1 ± 3.7 mg/g.
Conclusions: The delivery of nano-particles in PIPAC was feasible, but pegylated 
liposomal concentrations are lower than standard doxorubicin formulation. Probably 
mechanical and physical properties of pressurized aerosol chemotherapy might alter their 
stability and cause structural disintegration.
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INTRODUCTION
Peritoneal carcinomatosis (PC) is a clinical presentation both of 
different primary tumors (synchronous or metachronous) such 
as colon-rectum, ovarian, appendix, stomach, pancreas, liver, 
and primitive peritoneal neoplasms such as diffuse peritoneal 
mesothelioma and primary peritoneal adenocarcinomas. 
Historically, PC was considered an end-stage pathology and 
treated by palliative intent with debulking surgery and/or 
systemic chemotherapy, usually with poor results. However, in 
the last decades, the treatment of this peculiar cancer spread 
recorded a growth both in interest and technical improvements, 
drawing new outlines in the management of PC. Improvement in 
the treatment of PC follows the two main carcinomatosis features; 
indeed, some PC are amenable to combined treatment (systemic 
and loco-regional) with curative intent (or long-term survival 
expectations) and some others are, still nowadays, treated by 
palliative approach. Curative approach is, unfortunately, reserved 
to a minority of selected patients, while most of patients are still 
treated with palliative intent (due to comorbidity, advanced stage 
of disease, age limits, availability of specialized centers). The edge 
between those two major PC features is sometimes unclear and 
new ways to treat the “gray-zone patients,” merging low-impact 
treatment and acceptable clinical results may be, probably, the 
near-future ideal approach to PC.
As reported in literature, intraperitoneal chemotherapy 
(IPC) seems to be effective (Ceelen and Flessner, 2010), but 
pharmacological limitation such as poor drug distribution 
inside the abdominal cavity (bulky disease and adhesions) and 
technical problems related to the intraperitoneal catheter are 
responsible for an high rate of patients’ inability to complete the 
expected IPC cycles (Dedrick and Flessner, 1997; Wright et al., 
2015; Yamaguchi et al., 2015). One potential way to avoid the 
pharmacokinetic limitations of IPC is to apply IPC as a pressurized 
aerosol, taking advantage of the physical properties of gas and 
pressure (Alkhamesi et al., 2005) to spray a drug solution. On this 
base, PIPAC (pressurized intraperitoneal aerosol chemotherapy) 
has been recently introduced as a new approach to perform IPC; 
this treatment is based on the observation that under-pressure 
application of chemotherapy enhances tumor drug uptake 
(Jacquet et al., 1996; Esquis et al., 2006). PIPAC may be a way to 
increase distribution and penetration depth of IPC and achieved a 
superior distribution on the peritoneum and a better penetration 
into peritoneal nodules compared to conventional IPC in ex vivo 
models (Solass et al., 2012). The size of the particles has a major 
influence on their behavioral properties and the aerosol particle 
radius or diameter is a key property used to characterize aerosol. 
The micropump generates aerosol droplets with a mean diameter 
of 11 μm; droplet size is heterogeneous ranging from 3 to 15 μm 
after sedimentation.
So far, the drugs used in PIPAC are cisplatin, doxorubicin, and 
oxaliplatin but there are no data comparing different drugs and 
dosage schedules of PIPAC in patients with PC.
Nanoparticles with their sub-micron size, versatility of physical, 
chemical properties, and easily modifiable surface are uniquely 
poised to bypass the body clearing systems. They penetrate 
through extra-and intracellular barriers to deliver drugs into 
cancer cells thereby enhancing chemotherapeutic efficacy. Specific 
manipulation of the chemical composition of nanoparticles can 
significantly increase peritoneal residence time, thereby prolonging 
exposure of tumor to chemotherapeutic agents will increase the 
local drug concentration is primary goal of IPC (González-Moreno 
et al., 2010).
Pegylated liposomal doxorubicin (Doxil® or European trademark 
Caelyx®) is a formulation of doxorubicin in poly(ethylene glycol)- 
coated (stealth) liposomes with a prolonged circulation time 
and unique toxicity profile. Doxil® liposomes retain the drug 
payload during circulation and accumulate preferentially in 
tissues with increased microvascular permeability, as often is 
the case of tumors. The potential of Doxil® in the treatment 
of numerous cancer types and the opportunities it offers in 
combination with other drugs and therapeutic modalities 
are under active investigation.
Studies of nanoparticle–mucus interactions reveal that mucus 
interferes with penetration of nanoparticle through hydrogen 
bonding, adhesion, and electrostatic interactions (Lai et al., 2009). 
PEG coating has been used to minimize mucus–nanoparticle 
interaction thereby increasing nanoparticle penetration through 
mucus (Maisel et al., 2015).
The promising enhancement of the effectiveness of anticancer 
drugs encapsulate in nanoparticulate systems in a considerable 
aspect. Moreover, increased residence time, prolonged drug 
release over time, and decrease of adverse side effect are notable 
features of PIPAC application that could increase the positive 
features of Caelyx® (Nowacki et al., 2017). PIPAC therapeutic 
outcomes could be remarkably improved exploiting the 
combination with nanoparticulate systems.
Anyway, there have been only a few published papers that 
have fully referred to the potential use and initial experimental 
effects of nanoparticles and Near Infrared Irradiation (NIR) for 
Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) and none 
for PIPAC. One of the first publications addressing this topic is 
detailed review that suggested that the NIR/nanoparticle concept 
could improve HIPEC (Wu et al., 2015). To our knowledge, only 
one paper refers to the use HIPEC with pegylated liposomal 
doxorubicin (PLD) following maximal cytoreduction in patients 
with advanced abdominal-only gastrointestinal or gynecologic 
malignancies without any major postoperative complications 
(Harrison et al., 2008).
The aim of this study is to use doxorubicin in liposomal form 
in PIPAC procedure in order to assess feasibility, safety, and the 
possibility of greater penetration.
MATERIAL AND METHODS
Material
PLD (Caelyx®) is a formulation of doxorubicin in polyethylene 
glycol (PEG) coated Stealth® liposomes (Gabizon, 2001). 
“Pegylation” is the process whereby the doxorubicin-containing 
liposomes are enclosed within a PEG layer; pegylation protects 
the liposomes from detection by the mononuclear phagocyte 
system and provides a stabilization effect that reduces adhesion 
to cells, blood vessel walls, and other surfaces. During circulation, 
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at least 90% of PLD remains encapsulated within the liposomes, 
resulting in an extended half-life compared to conventional 
doxorubicin (Alberts et al., 2004). The active ingredient of the 
formulation is doxorubicin.
Doxorubicine hydrochloride solution was adriblastina 50 
mg/1 Vial by Pfizer.
Methods
PIPAC procedure was performed under general anesthesia 
and capnoperitoneum (12 mm Hg, 37°C) using a single-port 
access placed in the midline. Explorative laparoscopy allowed 
peritoneal cancer index (PCI) evaluation; parietal biopsies 
and ascites removal were performed. The increased intra-
abdominal pressure due to the capnoperitoneum increases the 
drug penetration into tumoral tissues. Using a micropump 
(Capnopen) the pressurized drug-containing solution was 
delivered into the abdominal cavity; doxorubicin or liposomal 
doxorubicin (1.5 mg/sm in 50 ml 0.9% NaCl). The aerosol was 
kept in a steady-state for 30 min and then exhausted through a 
closed filter system. At the end of the procedure tissue samples 
of the peritoneum were recovered from at least three abdominal 
quadrants.
Between June 2015 and December 2018, 206 PIPAC 
applications in 104 patients were performed.
For this study we considered 15 PIPAC procedures using 
Caelyx® at the dose of 1.5 mg/sm. Patients of this subgroup were 
treated within the framework of an off-label program. Access 
to this off-label study was limited to patients who had a life-
threatening disease with no satisfactory alternative therapies 
or could not enter a clinical trial. Data were compared with 
those obtained in 10 patients subjected to PIPAC with the same 
standard doxorubicin dosage. This sample of patients was taken 
as a control group from a larger patients’ cohort treated within 
the ongoing PI-CaP Protocol (number NCT02604784; EudraCT 
number 2015-000866-72).
All procedures were performed according to the principles of 
the Helsinki declaration; all patients were extensively informed 
and sign a consent inform.
Peritoneal samples were collected after 30 min of PIPAC treatment 
and frozen. Subsequently the tissue samples were homogenized and 
extracted and the drug concentration was determined by a High 
Performance Liquid Chromatography (HPLC) analysis.
Determination of Doxorubicin Tissue 
Concentration
Tissue extracts were prepared by adding in a test tube one volume 
of methanol and two volumes of 1 M Tris buffer with pH 8.5 
to the tissue. The mixtures were homogenized using polytron 
(Kinematica GMBH, Eschbach, Germany), and the tissue 
homogenates were kept on ice for 15 min before adding seven 
volumes of acetonitrile. The mixtures were vortexed and allowed 
to stand at room temperature for 15 min before removing the 
precipitated proteins by centrifugation at 3,000 × g for 5 min. After 
centrifugation, clear supernatants were assessed for doxorubicin 
content by HPLC using the method described below.
HPLC Quantitative Determination 
of Doxorubicin
Quantitative determination of doxorubicin was carried out by an 
HPLC system consisting of a pump (Shimadzu LC-9A PUMP C) 
equipped with fluorescence detector (Chrompack). Analyses 
were performed using an Agilent TC C18 column (250 mm × 
4.6 mm, 5 µm). The mobile phase was a mixture of KH2PO4 0.01 M 
(pH 1.4), acetonitrile, and methanol (65:25:10 v/v/v), degassed 
and pumped through the column with a flow rate of 1 ml/min. 
The column effluent was monitored at excitation and emission 
wavelengths of 480 and 560 nm, respectively. The external 
standard method was used to calculate the drug concentration. 
For this purpose, 1 mg of doxorubicin was weighed, placed in a 
volumetric flask, and dissolved in water to obtain a stock standard 
solution. This solution was then diluted using the mobile phase, 
providing a series of calibration solutions, subsequently injected 
into the HPLC system. Linear calibration curve was obtained 
over the concentration range of 5–100 ng/ml with a regression 
coefficient of 0.999.
Determination of Doxorubicin Plasma 
Concentration and Side Effects
No traces have been found in the peripheral blood for both 
doxorubicin and Caelyx®.
Postoperative mortality was nil. No differences were found 
between the two treatment groups. No patient reported major 
complications; in four cases (16%) minor complications were 
registered (nausea, abdominal pain). There were no alterations 
in hepatic and renal function, even after repeated PIPAC 
procedures. The median hospital stay was 2.3 days.
Statistical Analysis
Data are expressed as the mean ± standard error of the mean 
(SEM). Significant differences between experimental groups were 
detected by one-way ANOVA followed by Bonferroni correction 
using GraphPad InStat software (San Diego, CA, USA). A p value < 
0.05 was considered statistically significant.
RESULTS
This study aimed at the in vivo evaluation the tissue distribution of 
liposomal doxorubicin (Caelyx®) in abdominal cavity after PIPAC 
treatment in comparison to that of doxorubicin solution. Previous 
researches reported the distribution pattern and penetration 
depth of doxorubicin solution after PIPAC in postmortem swine 
model (Khosrawipour et al., 2016; Khosrawipour et al., 2017; 
Bellendorf et al., 2018).
Here, 24 tissue patient samples using Caelyx® and 39 using 
doxorubicin solution were collected and analyzed by HPLC 
analysis. Interestingly the drug penetrates and accumulates 
in the abdominal cavity tissues, without reaching the systemic 
circulation in detectable amount. These pharmacokinetic results 
confirm the loco-regional treatment and represent an advantage 
for decreasing adverse effects.
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Figure 1 showed the concentration of doxorubicin detected in 
the different tissue samples.
These results indicate a good drug biodistribution in all the 
tissues and it is in line with the data obtained by Khosarwipour 
in the ex vivo model (Khosrawipour et al., 2016). The maximum 
of the drug penetration was observed in the area in front of the 
microinjection pump (MIP) (that for the position of the operators 
they are usually the right diaphragmatic and parietal peritoneum, 
except for cases in which the MIP is directed towards the pelvis 
due to the presence of adhesions).
A statistically different doxorubicin tissue concentration 
was observed for the doxorubicin solution compared to PLD in 
the right parietal peritoneum and diaphragm. Overall, a mean 
tissue concentration of about 1.2 mg/g was observed after the 
administration of PLD, while it increased (2.5 fold) in the case of 
doxorubicin solution.
Indeed, the Caelyx® series a mean tissue concentration of 1.27 ± 
1.33 mg/g was reported, while in the second one we registered a 
mean concentration of 3.1 ± 3.7 mg/g. Therapeutic doxorubicin 
concentrations were observed following the administration of 
lower doses that generally ranged between 10 and 60 mg/m2. 
The lower tissue accumulation obtained with the PLD compared 
to the doxorubicin solution is in agreement with the ex vivo 
study of Mikolajczyk et al. (2018). They found minimal or no 
penetration with liposomal doxorubicin after PIPAC assuming 
that liposoma coating might inhibit the interaction between drug 
and peritoneal surface.
This behavior might be also related to the aerosol pressure 
that can favor the coalescence of the liposomal systems 
modifying their surface characteristics and drug release profile 
(Chattopadhyay et al., 2012).
DISCUSSION
The treatment of PC has evolved extraordinarily over the years 
from palliative approach to cytoreductive surgery techniques 
associated or not to different intraperitoneal drug delivery 
(HIPEC/EPIC). PIPAC is one of the most recent intraperitoneal 
delivery systems to improve peritoneal drug penetration. 
Currently PIPAC is still a palliative treatment, but the results 
obtained in terms of outcome and safety make it a very promising 
procedure.
The rational for trying nanoparticles in PIPAC is to take 
advantage of the antitumoral therapy as potential target for longer 
effectiveness in the peritoneal cavity: in fact, the instillation of 
a chemotherapy-containing nanoparticle may improve drug 
retention and the large molecular size of a nanoparticle would 
suggest slow clearance from the peritoneal cavity (De Smet 
et al., 2013).
The purpose of our pharmacokinetic study was to measure 
the penetration of doxorubicin and PLD within the peritoneal 
tissues after pressurized intraperitoneal aerosol administration. 
Our results demonstrate that PLD doesn’t penetrate the 
peritoneum and its release is probably inhibited by liposomal 
coating. Similar results were also obtained using PLD in 
HIPEC procedure (Sugarbaker and Stuart, 2019): the retention 
of PLD within the peritoneal tissues over a 90-min HIPEC is 
reported to be only approximately 20% and 180 min of HIPEC 
40%. The median area under the curve ratio of peritoneal fluid 
concentration times time as compared to plasma concentration 
times was over 1,000 and increased with dose escalation from 
50 to 100 mg/sm. When PLD was used for EPIC, the area under 
the curve ratios were similar to the HIPEC one but retention of 
FIGURE 1 | Amount of doxorubicin and pegylated liposomal doxorubicin in the different tissues (µg drug/g tissue). Results are expressed as mean ± SD. #p < 0.05 
vs. pegylated liposomal doxorubicin, *p < 0.01 vs. pegylated liposomal doxorubicin, by two-way ANOVA followed by Bonferroni post tests.
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drug within the peritoneal tissues was maintained for 24 h with 
approximately 80% drug utilization. The authors concluded that 
nanoparticle PLD is slowly absorbed into the intraperitoneal 
tissues and not appropriate for HIPEC, while EPIC is the 
preferred methodology for administration. Unfortunately, 
we could not verify the same effect in PIPAC in vivo since 
abdominal drains were not placed and it was not possible to take 
serial tissue and/or peritoneal fluid samples.
CONCLUSIONS
The preliminary results of this work demonstrated the feasibility 
of the delivery of PLD as pressurized aerosol (PIPAC). Tissue 
concentrations are lower than standard doxorubicin formulation. 
Further studies might optimize drug biodistribution tuning 
distance and pressure of the aerosol in PIPAC. The reduced doses 
and the local administration might decrease side effects and 
improve the quality of life of patients.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to 
the corresponding author.
AUTHOR CONTRIBUTIONS
The authors confirm that the final manuscript has been read, 
and each author’s contribution has been approved by the 
appropriate author. This paper has been seen and approved by 
all authors.
ACKNOWLEDGMENTS
We would like to show our gratitude to 13th International 
Symposium on Regional Cancer Therapies held on February 
17–19 in Jacksonville, FL; we had the possibility to present the 
preliminary results of our work in a poster.
REFERENCES
Alberts, D. S., Muggia, F. M., Carmichael, J., Winer, E. P., Jahanzeb, M., Venook, A. P., 
et   al. (2004). Efficacy and safety of liposomal anthracyclines in phase I/II 
clinical trials. Semin. Oncol. 31, 53–90. doi: 10.1053/j.seminoncol.2004.08.010
Alkhamesi, N. A., Ridgway, P. F., Ramwell, A., McCullough, P. W., Peck, D. 
H., and Darzi, A. W. (2005). Peritoneal nebulizer: a novel technique for 
delivering intraperitoneal therapeutics in laparoscopic surgery to prevent 
locoregional recurrence. Surg. Endosc. 19, 1142–1146. doi: 10.1007/
s00464-004-2214-3
Bellendorf, A., Khosrawipour, V., Khosrawipour, T., Siebigteroth, S., Cohnen, J., 
Diaz-Carballo, D., et al. (2018). Scintigraphic peritoneography reveals a non-
uniform. Surg. Endosc. 32, 166–174. doi: 10.1007/ s00464-017-5652-4
Ceelen, W. P., and Flessner, M. F. (2010). Intraperitoneal therapy for peritoneal 
tumors: biophysics and clinical evidence. Nat. Rev. Clin. Oncol. 7, 108–115. doi: 
10.1038/nrclinonc.2009.217
Chattopadhyay, S., Ehrman, S. H., Bellare, J., and Venkataraman, C. (2012). 
Morphology and bilayer integrity of small liposomes during aerosol 
generation by air-jet nebulisation | SpringerLink. J. Nanopart. Res. 14, 779. 
doi: 10.1007/s11051-012-0779-7
De Smet, L., Ceelen, W., Remon, J. P., and Vervaet, C. (2013). Optimization of 
drug delivery systems for intraperitoneal therapy to extend the residence 
time of the chemotherapeutic agent. ScientificWorldJournal 2013, 720858. doi: 
10.1155/2013/720858
Dedrick, R. L., and Flessner, M. F. (1997). Pharmacokinetic problems in peritoneal 
drug administration: tissue penetration and surface exposure. J. Natl. Cancer 
Inst. 89, 480–487. doi: 10.1093/jnci/89.7.480
Esquis, P., Consolo, D., Magnin, G., Pointaire, P., Moretto, P., Ynsa, M. D., et al. 
(2006). High intra-abdominal pressure enhances the penetration and antitumor 
effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. 
Ann. Surg. 244, 106–112. doi: 10.1097/01.sla.0000218089.61635.5f
Gabizon, A. A. (2001). Pegylated liposomal doxorubicin: metamorphosis of an 
old drug into a new form of chemotherapy. Cancer Invest. 19, 424–436. doi: 
10.1081/CNV-100103136
González-Moreno, S., González-Bayón, L. A., and Ortega-Pérez, G. (2010). 
Hyperthermic intraperitoneal chemotherapy: rationale and technique. World 
J. Gastrointest. Oncol. 2, 68–75. doi: 10.4251/wjgo.v2.i2.68
Harrison, L. E., Bryan, M., Pliner, L., and Saunders, T. (2008). Phase I trial 
of pegylated liposomal doxorubicin with hyperthermic intraperitoneal 
chemotherapy in patients undergoing cytoreduction for advanced intra-
abdominal malignancy. Ann. Surg. Oncol. 15, 1407–1413. doi: 10.1245/
s10434-007-9718-8
Jacquet, P., Stuart, O. A., Chang, D., and Sugarbaker, P. H. (1996). Effects of 
intra-abdominal pressure on pharmacokinetics and tissue distribution of 
doxorubicin after intraperitoneal administration. Anticancer Drugs 7, 596–603. 
doi: 10.1097/00001813-199607000-00016
Khosrawipour, V., Khosrawipour, T., Kern, A. J., Osma, A., Kabakci, B., Diaz-Carballo, 
D., et al. (2016). Distribution pattern and penetration depth of doxorubicin after 
pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine 
model. J. Cancer Res. Clin. Oncol. 142, 2275–2280. doi: 10.1007/s00432-016-2234-0
Khosrawipour, V., Khosrawipour, T., Hedayat-Pour, Y., Diaz-Carballo, D., 
Bellendorf, A., Boese-Ribeiro, H., et al. (2017). Effect of whole-abdominal 
Irradiation on penetration depth of doxorubicin in normal tissue after 
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in a post-mortem 
swine model. Anticancer Res. 37, 1677–1680. doi: 10.21873/anticanres.11498
Lai, S. K., Wang, Y. Y., and Hanes, J. (2009). Mucus-penetrating nanoparticles for 
drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61, 158–171. 
doi: 10.1016/j.addr.2008.11.002
Maisel, K., Ensign, L., Reddy, M., Cone, R., and Hanes, J. (2015). Effect of 
surface chemistry on nanoparticle interaction with gastrointestinal mucus 
and distribution in the gastrointestinal tract following oral and rectal 
administration in the mouse. J. Control. Release 197, 48–57. doi: 10.1016/j.
jconrel.2014.10.026
Mikolajczyk, A., Khosrawipour, V., Schubert, J., Grzesiak, J., Chaudhry, H., Pigazzi, A., 
et al. (2018). Effect of liposomal doxorubicin in Pressurized Intra-Peritoneal 
Aerosol Chemotherapy (PIPAC). J. Cancer 9, 4301–4305. doi: 10.7150/jca.26860
Nowacki, M., Peterson, M., Kloskowski, T., McCabe, E., Guiral, D. C., Polom, K., 
et al. (2017). Nanoparticle as a novel tool in hyperthermic intraperitoneal and 
pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal 
carcinomatosis. Oncotarget 8, 78208–78224. doi: 10.18632/oncotarget.20596
Solass, W., Herbette, A., Schwarz, T., Hetzel, A., Sun, J. S., Dutreix, M., et al. 
(2012). Therapeutic approach of human peritoneal carcinomatosis with 
Dbait in combination with capnoperitoneum: proof of concept. Surg. 
Endosc. 26, 847–852. doi: 10.1007/s00464-011-1964-y
Sugarbaker, P. H., and Stuart, O. A. (2019). Pharmacokinetics of the 
intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients 
with peritoneal metastases. Eur. J. Surg. Oncol. doi: 10.1016/j.ejso. 2019.03. 
035
Wright, A. A., Cronin, A., Milne, D. E., Bookman, M. A., Burger, R. A., Cohn, D. E., 
et al. (2015). Use and effectiveness of intraperitoneal chemotherapy for treatment 
of ovarian cancer. J. Clin. Oncol. 33, 2841–2847. doi: 10.1200/JCO.2015.61.4776
Wu, C. C., Yang, Y. C., Hsu, Y. T., Wu, T. C., Hung, C. F., Huang, J. T., et al. (2015). 
Nanoparticle-induced intraperitoneal hyperthermia and targeted photoablation in 
treating ovarian cancer. Oncotarget 6, 26861–26875. doi: 10.18632/oncotarget.4766
A New Locoregional Approach to Peritoneal CarcinomatosisRobella et al.
6 June 2019 | Volume 10 | Article 669Frontiers in Pharmacology | www.frontiersin.org
Yamaguchi, H., Kitayama, J., Ishigami, H., Kazama, S., Nozawa, H., Kawai, K., 
et al. (2015). Breakthrough therapy for peritoneal carcinomatosis of gastric 
cancer: intraperitoneal chemotherapy with taxanes. World J. Gastrointest 
Oncol. 7, 285–291. doi: 10.4251/wjgo.v7.i11.285
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2019 Robella, Vaira, Argenziano, Cavalli, Spagnolo, Borsano, 
Gentilli and De Simone. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the 
original author(s) and the copyright owner(s) are credited and that the original 
publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
